Co-Authors
This is a "connection" page, showing publications co-authored by RUSSELL BROADDUS and ANIL K SOOD.
Connection Strength
1.013
-
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785.
Score: 0.192
-
Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473.
Score: 0.155
-
Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res. 2014 Apr 01; 20(7):1846-55.
Score: 0.118
-
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15; 10(12):1306-14.
Score: 0.095
-
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009 Jun 15; 115(12):2684-92.
Score: 0.086
-
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007 Dec 15; 13(24):7487-95.
Score: 0.077
-
Erratum to: MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol. 2017 10 06; 10(1):163.
Score: 0.038
-
Metastasis regulation by PPARD expression in cancer cells. JCI Insight. 2017 01 12; 2(1):e91419.
Score: 0.036
-
MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol. 2016 10 19; 9(1):112.
Score: 0.036
-
Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol. 2015 Jul; 1(4):486-94.
Score: 0.033
-
Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014 Sep; 106(9).
Score: 0.031
-
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013 Feb 11; 23(2):186-99.
Score: 0.028
-
Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma. PLoS One. 2012; 7(5):e36383.
Score: 0.026
-
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.
Score: 0.026
-
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther. 2006 Sep; 5(9):1136-41.
Score: 0.018
-
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3.
Score: 0.018